Inovio Pharmaceuticals (INO) Operating Expenses (2010 - 2026)

Inovio Pharmaceuticals has disclosed Operating Expenses across 17 years of filings, most recently posting $18.6 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 19.32% year-over-year to $18.6 million; the TTM figure through Jun 2026 stood at $79.3 million (down 17.47% YoY), while the FY2025 annual figure was $86.9 million, down 22.85% from the prior year.
• Operating Expenses came in at $18.6 million for Q2 2026 at Inovio Pharmaceuticals, down from $21.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $104.9 million in Q2 2022 to a low of $17.5 million in Q4 2025.
• Average Operating Expenses over 5 years is $36.8 million, with a median of $29.5 million recorded in 2023.
• Year-over-year, Operating Expenses jumped 35.91% in 2022 and sank 64.48% in 2023.
• Over 5 years, Operating Expenses stood at $56.1 million in 2022, then sank by 50.96% to $27.5 million in 2023, then slipped by 25.49% to $20.5 million in 2024, then decreased by 14.69% to $17.5 million in 2025, then climbed by 6.57% to $18.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $18.6 million in Q2 2026, $21.9 million in Q1 2026, and $17.5 million in Q4 2025.